A clinical study, led by researchers from University College Dublin, Ireland, and Stanford University, California, USA, with international collaborators, demonstrates that mortality rates of HIV patients can be almost halved when early antiretroviral (ARV) therapy is added to the treatment of AIDS-related opportunistic infections (OIs) such as pneumonia, meningitis or other serious bacterial infections.
The researchers are part of the AIDS Clinical Trials Group, the world’s largest clinical trial organization, and their scientific findings, published in PLosONE, recommend changes in the treatment regimes for HIV patients worldwide.